Inhaled Molgramostim Improved Exercise Capacity
Phase 3 clinical trial data shows improvements in walking distance and duration for patients with autoimmune pulmonary alveolar proteinosis treated with inhaled molgramostim.
Category: Clinical Trials
Clinical Trials
Latest
Inhaled Molgramostim Improved Exercise Capacity
Phase 3 clinical trial data shows improvements in walking distance and duration for patients with autoimmune pulmonary alveolar proteinosis treated with inhaled molgramostim.
Read More
Nebulized Treprostinil Preserved IPF Lung Function
Phase 3 trial results show significant reductions in clinical worsening and acute exacerbations for patients with idiopathic pulmonary fibrosis (IPF).
Read More
Inhaled Nitric Oxide Therapy Alx1 Well Tolerated in Ph1 Trial
Phase 1 data for the investigational inhaled nitric oxide therapy Alx1 demonstrated the treatment was well tolerated with no serious side effects in healthy volunteers.
Read More
Nebulized Dual Bronchodilator Aero-007 Improved COPD Lung Function
AERO-007 demonstrated significant lung function improvements over 24 hours in patients with moderate-to-severe COPD.
Read More
Alpha-1 Drug Candidate Superior to Standard Care
Phase 2 data for efdoralprin alfa demonstrate the recombinant protein maintains normal protein levels with less frequent dosing than current standards of care for patients with alpha-1 antitrypsin deficiency (AATD)-related emphysema.
Read More
Tezepelumab Reduced Asthma Attacks
A new study shows tezepelumab (Tezspire) reduced asthma exacerbations by 70% across all patient subgroups, including smokers and those with comorbid conditions.
Read More
Sleep Apnea Pill Reduced Breathing Interruptions
A phase 3 trial found that AD109 (aroxybutynin and atomoxetine) reduced breathing interruptions and improved oxygen levels in patients with obstructive sleep apnea.
Read More
Enanta Pharma to Present Data for RSV, STAT6 Therapies at ATS 2026
Enanta Pharmaceuticals will present data on its RSV therapy zelicapavir and on EPS-3903, an oral STAT6 inhibitor, at ATS 2026.
Read More
New Data on Inhaled Treprostinil for IPF
Data from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.
Read More
Phase 1 Data Incoming for ALX1 iNO Therapy
Phase 1 results for the inhaled drug candidate ALX1 focus on safety and pharmacokinetics for the treatment of serious lung diseases.
Read More
Phase II Trial for Antiviral Nasal Spray Advances to Next Stage
The once-weekly INNA-051 treatment from ENA Respiratory aims to prime the immune system to protect high-risk patients from influenza, RSV, and other respiratory viruses.
Read More
ALA Launches Study to Test Omalizumab for COPD Flare-ups
The COPD-OMA trial will examine if the asthma drug omalizumab (Xolair) benefits COPD patients with sensitivities to indoor allergens.
Read More
Tozorakimab Reduces COPD Flare-Ups in Ph3 Trial
The MIRANDA study found tozorakimab significantly lowered the rate of moderate-to-severe respiratory worsening in patients regardless of smoking history or specific white blood cell counts.
Read More
FDA Launches Real-Time Clinical Trial Initiative
The FDA is testing a new framework for monitoring safety signals as trials progress to reduce...
Read More
Deupirfenidone May Stabilize IPF Lung Function
Data from the Phase 2b ELEVATE IPF trial suggest deupirfenidone maintains efficacy while offering a favorable safety and tolerability profile.
Read More
Inhaled Treprostinil Improves IPF Lung Function
Results from the TETON-1 study show nebulized Treprostinil (Tyvaso) met its primary endpoint, demonstrating a significant increase in IPF lung function compared to placebo.
Read More
Rademikibart Tied to Rapid Lung Function Improvement in Asthma, COPD
Phase 1 study revealed significant FEV1 improvements within 15 min of a single dose of IV rademikibart — an antibody targeting interleukin-4 receptor alpha.
Read More
Inhaled Pirfenidone May Stabilize Lung Fibrosis Scores
More than 70% of IPF patients receiving inhaled pirfenidone achieved stabilization or improvement in fibrosis scores at 24 weeks.
Read More
Tozorakimab Reduced COPD Exacerbations in Ph3 Trials
The monoclonal antibody Tozorakimab showed significant clinical benefit in reducing COPD flare-ups for a broad range of patients, including former and current smokers.
Read More
Positive Ph3 Arikayce Data for MAC Lung Disease
The ENCORE study showed that adding an inhaled amikacin suspension to multidrug therapy improved respiratory symptoms and increased culture conversion rates.
Read More
Natural Fungal Supplement Improved COVID-19 Vaccine Response
Participants with no prior exposure to SARS-CoV-2 experienced fewer vaccine side effects and continued increases in antibody levels over six months.
Read More
Metformin, UDCA Fail to Improve Long COVID Recovery
A two-week course of metformin or ursodeoxycholic acid (UDCA) did not meaningfully improve recovery from long COVID symptoms.
Read More
Positive Ph3 Trial Data Treating Uncontrolled Asthma with Breztri
AstraZeneca’s Breztri Aerosphere demonstrated statistically significant and clinically meaningful improvements in patients with uncontrolled asthma compared with other pharmacology.
Read More
Comparing Daily vs Weekly Pharmacology for Tuberculosis
A study in Brazil found that a 30-day daily TB preventive therapy regimen was as safe and effective as the standard 90-day weekly regimen.
Read More